The preceding six modules established the pharmacology of antianginal drug classes, agents selected primarily to relieve ischemic symptoms by reducing myocardial oxygen demand or increasing supply. This module addresses a pharmacologically distinct but clinically inseparable layer of stable coronary artery disease management: the cardioprotective background therapy that every patient with established coronary artery disease requires, regardless of which antianginal agents are chosen for symptom control.1·2
The distinction between antianginal therapy (symptom control) and cardioprotective therapy (prognostic benefit) is one of the most clinically consequential distinctions in cardiovascular pharmacology. Nitrates, calcium channel blockers, ranolazine, and ivabradine reduce anginal episodes and improve quality of life; they do not reduce mortality in stable coronary artery disease. Beta-blockers reduce mortality specifically in the post-myocardial infarction context.1·2 The agents reviewed in this module, namely antiplatelet drugs, statins, and renin-angiotensin system inhibitors, have demonstrated reductions in hard cardiovascular outcomes (myocardial infarction, stroke, cardiovascular death) in stable coronary artery disease, independent of their antianginal properties.1·2·3 Understanding their pharmacology, evidence base, and clinical integration is inseparable from rational antianginal prescribing.
Platelet activation is central to the pathophysiology of acute coronary syndromes and contributes to the chronic thrombotic milieu within atherosclerotic coronary arteries.4 Even in stable coronary artery disease without recent acute coronary syndrome, atherosclerotic plaque is a continuous source of platelet activation: dysfunctional endothelium over plaque surfaces has reduced nitric oxide and prostacyclin production, allowing platelet adhesion, activation, and microthrombus formation.4 The rupture or erosion of vulnerable plaques, the event that converts stable angina to acute myocardial infarction, is invariably followed by platelet-rich thrombus formation that is the immediate cause of coronary occlusion.4 Antiplatelet therapy addresses this biology at the pharmacological level: it reduces platelet aggregation at plaque surfaces and attenuates the thrombotic response to plaque disruption, thereby reducing the risk of acute ischemic events.1·2·4
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets by covalently acetylating a serine residue in the enzyme active site.4 COX-1 catalyzes the conversion of arachidonic acid to thromboxane A2, a potent platelet activator and vasoconstrictor. Because mature platelets have no nucleus and cannot synthesize new COX-1 protein, a single aspirin dose produces irreversible platelet inhibition for the entire 7-10 day platelet lifespan.4 COX-1 inhibition also reduces the production of prostacyclin (prostaglandin I2) in endothelial cells, which is an antiplatelet and vasodilatory eicosanoid. However, endothelial cells can regenerate COX-1 and resume prostacyclin synthesis within hours because they are nucleated; the net effect of aspirin therefore favors inhibition of platelet thromboxane A2 over prostacyclin, producing a net antithrombotic effect.4 The antithrombotic dose of aspirin is 75-100 mg daily, substantially lower than the anti-inflammatory dose of 600-1000 mg three to four times daily.4 Higher doses of aspirin do not provide greater antiplatelet benefit and increase gastrointestinal adverse effects; they also progressively inhibit endothelial prostacyclin, potentially attenuating the antithrombotic advantage.4
Aspirin 75-100 mg daily reduces the risk of major adverse cardiovascular events by approximately 25-30% in patients with established coronary artery disease (secondary prevention), with an absolute risk reduction that is substantial given the high baseline risk of this population.1·2 The Antithrombotic Trialists' Collaboration meta-analysis of over 135,000 patients in secondary prevention demonstrated consistent reductions in non-fatal myocardial infarction, non-fatal stroke, and vascular death.5 Aspirin is guideline-recommended (Class I) for all patients with stable coronary artery disease without absolute contraindications.1·2
Adverse effects and risk of aspirin: gastrointestinal bleeding is the most clinically important adverse effect, occurring in approximately 1-2% of patients per year on low-dose aspirin.4 Risk is higher with higher doses, concurrent non-steroidal anti-inflammatory drug use, peptic ulcer disease history, Helicobacter pylori infection, older age, and anticoagulant co-therapy. Enteric coating does not reliably reduce gastrointestinal bleeding risk in clinical trials despite reducing dyspepsia. Proton pump inhibitor co-therapy is recommended for patients at elevated gastrointestinal bleeding risk.4 In primary prevention, in patients without established coronary artery disease, the absolute benefit of aspirin is smaller and the net benefit over bleeding risk is uncertain or negative in low-risk individuals; aspirin is therefore no longer broadly recommended for primary prevention per 2019 ACC/AHA guidelines.1 This does NOT affect its clear benefit in secondary prevention (patients with established coronary artery disease).1
Clopidogrel is a thienopyridine prodrug that requires hepatic bioactivation primarily via CYP2C19 (cytochrome P450 2C19) to generate an active thiol metabolite.4 The active metabolite irreversibly binds the platelet P2Y12 adenosine diphosphate (ADP) receptor, blocking ADP-induced platelet aggregation for the platelet lifespan.4 The pharmacological complementarity between aspirin (COX-1/thromboxane pathway) and clopidogrel (P2Y12/ADP pathway) is the rationale for dual antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.4
In stable coronary artery disease without recent acute coronary syndrome or coronary stenting, clopidogrel 75 mg daily is the preferred alternative to aspirin when aspirin is contraindicated or not tolerated (typically due to aspirin hypersensitivity or severe gastrointestinal intolerance despite proton pump inhibitor therapy).1·2 The CAPRIE trial (Bhatt et al.) demonstrated that clopidogrel was marginally superior to aspirin in reducing the composite endpoint of ischemic stroke, myocardial infarction, and vascular death in patients with atherosclerotic disease, primarily driven by a benefit in peripheral arterial disease patients.6 For stable coronary artery disease without recent acute coronary syndrome, clopidogrel is an equivalent-to-superior aspirin substitute rather than an add-on.1·2
CYP2C19 pharmacogenomics and clopidogrel: the conversion of clopidogrel to its active metabolite requires CYP2C19.4 Patients who are CYP2C19 poor metabolizers, approximately 2-14% of populations depending on ethnicity (higher in East Asian populations), generate substantially less active metabolite and have reduced platelet inhibition.4 This loss-of-function CYP2C19 variation is associated with higher rates of stent thrombosis and major adverse cardiovascular events in patients treated with clopidogrel after acute coronary syndrome. FDA labeling includes a boxed warning regarding CYP2C19 poor metabolizers. Strong CYP2C19 inhibitors, specifically omeprazole and esomeprazole (proton pump inhibitors commonly co-prescribed with antiplatelet therapy), reduce clopidogrel activation and platelet inhibition, though the clinical significance of this interaction for outcomes in stable coronary artery disease remains debated.4 Pantoprazole has less CYP2C19 inhibitory activity and is generally preferred when proton pump inhibitor co-therapy is required in clopidogrel-treated patients.4
Dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) is the standard of care for 12 months following acute coronary syndrome with or without percutaneous coronary intervention, and for a duration determined by stent type after elective percutaneous coronary intervention.7 This module focuses on the stable angina context, where the relevant decision is the duration and continuation of antiplatelet therapy in patients who have transitioned from an acute coronary syndrome or post-procedure period to stable chronic coronary artery disease.
After completing the standard dual antiplatelet therapy duration following acute coronary syndrome, patients return to aspirin monotherapy (75-100 mg daily) as long-term secondary prevention.1·2 In patients at particularly high ischemic risk and low bleeding risk, extended dual antiplatelet therapy (DAPT) beyond 12 months may be considered; the DAPT trial and PEGASUS-TIMI 54 trial (ticagrelor 60 mg twice daily plus aspirin) showed reduced ischemic events with extended dual antiplatelet therapy in selected post-myocardial infarction patients, balanced against increased bleeding risk.7 The net benefit of extended dual antiplatelet therapy requires individual risk-benefit assessment and is not a blanket recommendation for all stable coronary artery disease patients.1·2
In patients with stable coronary artery disease who also require oral anticoagulation for concurrent indications (atrial fibrillation, mechanical heart valve, or venous thromboembolism), the combination of antiplatelet therapy and anticoagulation substantially increases bleeding risk.7 For patients with stable coronary artery disease on oral anticoagulation for atrial fibrillation (typically a direct oral anticoagulant), chronic addition of aspirin is not routinely recommended beyond approximately one year after any recent acute coronary syndrome or stenting; anticoagulation alone provides sufficient protection for atrial fibrillation stroke prevention and reduces the bleeding risk compared with triple therapy.7 The decision must be individualized based on ischemic and hemorrhagic risk scores.7
Statins (hydroxymethylglutaryl-coenzyme A reductase inhibitors) are competitive inhibitors of the rate-limiting enzyme in hepatic cholesterol synthesis.8 Inhibition of HMG-CoA reductase reduces intracellular cholesterol production in hepatocytes. The resulting decrease in intracellular cholesterol concentration upregulates hepatic low-density lipoprotein receptor expression via the SREBP-2 (sterol regulatory element-binding protein 2) transcription pathway, increasing LDL receptor-mediated clearance of LDL cholesterol from the circulation.8 The net effect is a dose-dependent reduction in plasma LDL cholesterol, the primary mechanism of cardiovascular risk reduction. High-intensity statins (atorvastatin 40-80 mg daily, rosuvastatin 20-40 mg daily) reduce LDL cholesterol by approximately 50-60% from baseline.8
Beyond LDL reduction, statins exert pleiotropic effects that may contribute to cardiovascular benefit: improvement of endothelial function via increased endothelial nitric oxide synthase expression, reduction in inflammatory markers (C-reactive protein), plaque stabilization through reduction in macrophage-derived metalloproteinase activity, and antithrombotic effects via reduced platelet thromboxane production.8 The relative contribution of pleiotropic effects versus LDL reduction to clinical outcomes remains debated, but large outcome trials have demonstrated that cardiovascular benefit is closely correlated with the absolute magnitude of LDL reduction regardless of baseline LDL level.8
The evidence base for statins in secondary prevention is among the strongest in cardiovascular pharmacology. The 4S trial (Scandinavian Simvastatin Survival Study) established that simvastatin 20-40 mg reduced total mortality, coronary death, and major coronary events in patients with coronary artery disease and elevated cholesterol.8 The Heart Protection Study (Collins et al., Lancet 2002) enrolled 20,536 patients at high cardiovascular risk including those with coronary artery disease, peripheral arterial disease, and diabetes, and demonstrated that simvastatin 40 mg reduced the rate of major vascular events by approximately one-fifth, with benefit consistent across patients with baseline LDL cholesterol below as well as above 3.0 mmol/L, establishing that the primary driver of benefit was relative LDL reduction rather than achievement of a fixed LDL target.8 The PROVE-IT TIMI 22 trial (Cannon et al., NEJM 2004) compared pravastatin 40 mg versus atorvastatin 80 mg in patients with recent acute coronary syndromes and demonstrated significantly superior outcomes with high-intensity statin therapy (atorvastatin 80 mg), establishing the principle of high-intensity statin therapy as the standard in secondary prevention.8 The TNT trial (LaRosa et al., NEJM 2005) confirmed this in stable coronary artery disease: atorvastatin 80 mg versus 10 mg produced significantly fewer major cardiovascular events, supporting high-intensity therapy even in stable (not recently acute) disease.8
Current guidelines (ACC/AHA 2018 Cholesterol Guideline) recommend high-intensity statin therapy as the default for all patients aged 20-75 with established atherosclerotic cardiovascular disease, including stable coronary artery disease.8 A treatment LDL target of below 70 mg/dL is recommended; in very high-risk patients (multiple major atherosclerotic cardiovascular disease events or one major event plus multiple high-risk conditions), a target of below 55 mg/dL is a reasonable goal.8 If the maximum-tolerated statin dose does not achieve sufficient LDL reduction, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can be added.8
Atorvastatin is the most widely prescribed statin in secondary prevention. Metabolism: CYP3A4 (cytochrome P450 3A4) (predominantly). Active metabolites: yes; ortho- and para-hydroxy metabolites retain substantial HMG-CoA reductase inhibitory activity and extend the effective duration of action beyond the parent compound's plasma half-life of approximately 14 hours.8 Bioavailability: ~14% due to first-pass metabolism. Dosing: 10-80 mg once daily; can be taken at any time of day (unlike some other statins). CYP3A4 drug interactions: strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, verapamil, diltiazem at higher doses) substantially increase atorvastatin plasma levels and myopathy risk; the simvastatin 80 mg dose cap in the US was established after similar CYP3A4 interaction concerns with simvastatin.8 In patients receiving verapamil or diltiazem for angina, atorvastatin is permissible but doses should be kept at or below 20 mg daily; rosuvastatin or pravastatin are safer alternatives in this combination.8
Rosuvastatin is the highest-potency statin available and does not undergo significant CYP3A4 metabolism (primarily eliminated via CYP2C9 (cytochrome P450 2C9) with a large renal component).8 This makes it the preferred statin in patients receiving CYP3A4-inhibiting antianginal drugs (verapamil, diltiazem) and in patients with multiple CYP3A4 drug interactions. Bioavailability: ~20% (higher than atorvastatin). Half-life: approximately 19 hours, supporting once-daily dosing. Dosing: 5-40 mg once daily; 20-40 mg constitutes high-intensity therapy. Renal excretion is proportionally greater than for atorvastatin; dose reduction to maximum 10 mg daily is recommended in severe chronic kidney disease (eGFR below 30 mL/min/1.73m2).8
Pravastatin is a hydrophilic statin that does not undergo significant CYP metabolism (sulfation is the primary metabolic route) and has minimal drug interaction potential via CYP pathways.8 It is a moderate-intensity statin (40-80 mg provides approximately 30-40% LDL reduction) and is appropriate when CYP3A4 or CYP2C9 interactions are a concern. It is also preferred in patients with significant hepatic impairment because it does not depend on hepatic CYP systems for clearance.8
Simvastatin was historically the benchmark secondary prevention statin but has been substantially displaced by atorvastatin and rosuvastatin due to its multiple drug interactions and regulatory dose cap.8 Simvastatin is a CYP3A4-metabolized prodrug (activated in vivo); CYP3A4 inhibitors, including verapamil (limit simvastatin to 10 mg daily), diltiazem (limit to 10 mg daily), amiodarone (limit to 20 mg daily), and amlodipine (limit to 20 mg daily at higher concentrations), all reduce simvastatin metabolism and increase myopathy risk.8 The FDA placed a cap on simvastatin 80 mg in 2011 due to myopathy risk; patients already tolerating 80 mg may continue but this dose should not be newly prescribed.8
Statin-associated myopathy encompasses a spectrum from asymptomatic creatine kinase elevation through myalgia with normal creatine kinase, to myositis (elevated creatine kinase with symptoms), to the rare but serious rhabdomyolysis (markedly elevated creatine kinase, myoglobinuria, acute kidney injury).8 The absolute risk of myalgia is approximately 5-10% in clinical practice (higher than in trials due to healthy user effects in trials) and rhabdomyolysis occurs in approximately 1-2 per 100,000 patient-years of statin use.8 Risk factors for statin-associated myopathy include advanced age, female sex, low body mass index, hypothyroidism (unrecognized), chronic kidney disease, high-dose statin therapy, and drug interactions that raise statin plasma concentrations (CYP3A4 inhibitors with atorvastatin or simvastatin).8 The mechanism is incompletely understood but involves impairment of mitochondrial coenzyme Q10 synthesis (statins reduce mevalonate pathway products including coenzyme Q10, which is essential for mitochondrial electron transport), reduction in cholesterol-dependent membrane repair mechanisms in skeletal muscle, and possible inhibition of small GTPases.8 Management involves dose reduction or switching to a lower-intensity statin; when myalgia is intolerable on all statins, ezetimibe or PCSK9 inhibitors may be used.8 Baseline and periodic creatine kinase monitoring is not routinely recommended in asymptomatic patients but should be obtained if myopathy symptoms develop.8
ACE inhibitors and angiotensin receptor blockers produce antihypertensive effects through blockade of the renin-angiotensin-aldosterone system, which is mechanistically well established. Less intuitively, these agents also reduce cardiovascular events in stable coronary artery disease patients who are normotensive or minimally hypertensive, demonstrating a cardioprotective mechanism that extends beyond simple blood pressure reduction.2·3·9 ACE inhibitors reduce the conversion of angiotensin I to angiotensin II by inhibiting the angiotensin-converting enzyme; they also prevent the degradation of bradykinin, which accumulates and stimulates endothelial nitric oxide and prostacyclin synthesis, contributing to vasodilation, anti-inflammatory effects, and antiproliferative actions on smooth muscle.9 Angiotensin II via its type 1 receptor promotes vasoconstriction, aldosterone secretion, sympathetic activation, endothelial dysfunction, vascular smooth muscle proliferation, oxidative stress, and adverse cardiac remodeling. Blocking angiotensin II generation (ACE inhibitor) or action (angiotensin receptor blocker) reduces all of these effects.9
In atherosclerotic coronary artery disease, the endothelium is dysfunctional, renin-angiotensin system activity is upregulated locally within the coronary arterial wall, and bradykinin degradation is accelerated. ACE inhibition reverses these abnormalities by simultaneously reducing angiotensin II and preserving bradykinin, improving endothelial function, reducing plaque inflammation, and limiting the adverse remodeling response to ischemic injury.9
The HOPE trial (Heart Outcomes Prevention Evaluation, Yusuf et al., NEJM 2000) enrolled 9,297 patients with established cardiovascular disease or diabetes plus one cardiovascular risk factor; the majority had coronary artery disease.9 Ramipril 10 mg daily versus placebo produced a 22% relative risk reduction in the composite of myocardial infarction, stroke, and cardiovascular death over five years, with an absolute risk reduction of 3.8 percentage points. Only one-half of the benefit could be attributed to blood pressure reduction, with the remainder attributed to direct vascular effects of ACE inhibition.9 This trial established the principle of ACE inhibitor use in coronary artery disease patients regardless of blood pressure level or left ventricular function.9 The EUROPA trial (EURopean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease, Fox et al., Lancet 2003) enrolled 12,218 patients with stable coronary artery disease and no known heart failure; perindopril 8 mg daily reduced the primary composite endpoint of cardiovascular death, myocardial infarction, and cardiac arrest by 20%.9 The PEACE trial (Prevention of Events with Angiotensin-Converting Enzyme Inhibition, Braunwald et al., NEJM 2004) enrolled patients with stable coronary artery disease and preserved left ventricular function and found no significant benefit from trandolapril; the discrepancy likely reflecting differences in baseline cardiovascular risk between the PEACE population (lower risk) and the HOPE and EUROPA populations.9 The net interpretation from the evidence is that ACE inhibitor benefit in stable coronary artery disease is most robust in higher-risk patients (impaired left ventricular function, diabetes, hypertension, multi-vessel disease, or established atherosclerotic disease at multiple sites).9
Current guideline recommendations: ACC/AHA 2012 Stable Ischemic Heart Disease Guideline and ESC 2019 Chronic Coronary Syndromes Guideline both recommend ACE inhibitors (Class I) in all stable coronary artery disease patients with left ventricular ejection fraction below 40%, hypertension, diabetes, or chronic kidney disease, and as a reasonable option (Class IIa) in all other stable coronary artery disease patients.1·2·9
Angiotensin receptor blockers (ARBs) block the angiotensin II type 1 receptor directly, preventing all effects of angiotensin II regardless of its route of generation (ACE-dependent and ACE-independent pathways).9 Unlike ACE inhibitors, ARBs do not inhibit bradykinin degradation; they therefore lack the bradykinin-mediated benefits (enhanced nitric oxide, prostacyclin production) and also lack the cough that ACE inhibitors produce in approximately 10-15% of patients (due to bradykinin and substance P accumulation in the airways).9 The ONTARGET trial (Telmisartan Alone and in combination with Ramipril Global Endpoint Trial, NEJM 2008) enrolled 25,620 patients with established cardiovascular disease or diabetes at high cardiovascular risk and directly compared telmisartan 80 mg with ramipril 10 mg, finding non-inferiority of telmisartan for the primary cardiovascular composite endpoint with a lower rate of angioedema and cough.9 The combination of telmisartan plus ramipril produced more adverse effects (hypotension, renal impairment, hyperkalemia) without additional cardiovascular benefit and is not recommended.9 ARBs are therefore the appropriate alternative to ACE inhibitors in patients who develop ACE inhibitor-induced cough; they are not superior to ACE inhibitors and should not be combined with them.1·2·9
Aldosterone antagonists (spironolactone and eplerenone) block mineralocorticoid receptors in the kidney, heart, and vasculature. Their role in stable coronary artery disease is largely established in the setting of reduced left ventricular ejection fraction.9 The RALES trial demonstrated that spironolactone 25-50 mg daily reduced mortality in severe heart failure with reduced ejection fraction (NYHA III-IV, ejection fraction below 35%). The EPHESUS trial demonstrated that eplerenone 25-50 mg daily, initiated within three to fourteen days of myocardial infarction complicated by left ventricular dysfunction (ejection fraction below 40%) and heart failure or diabetes, reduced cardiovascular death and hospitalization by approximately 15%.9 These trials define the established indications: aldosterone antagonists are recommended (Class I) in stable coronary artery disease patients with ejection fraction at or below 40% who are already on ACE inhibitor and beta-blocker therapy, and who have symptoms of heart failure or diabetes following myocardial infarction.9 In patients with normal ejection fraction and stable angina, aldosterone antagonists do not have an established mortality benefit and are not routinely indicated for coronary artery disease alone.9 Monitoring for hyperkalemia (target potassium below 5.0 mEq/L) and renal function is mandatory at initiation and periodically thereafter.9
ACE inhibitors and ARBs produce clinically important interactions relevant to the stable coronary artery disease patient.9 Potassium-sparing agents (spironolactone, eplerenone, amiloride, triamterene) and potassium supplements combined with ACE inhibitors or ARBs carry a risk of hyperkalemia that is elevated in patients with renal impairment, diabetes, or high baseline potassium.9 In the stable coronary artery disease patient who is already on a beta-blocker (which mildly raises potassium), an ACE inhibitor, and an aldosterone antagonist, the cumulative potassium-raising effect requires regular monitoring. Non-steroidal anti-inflammatory drugs reduce the antihypertensive and renoprotective efficacy of ACE inhibitors and ARBs by inhibiting prostaglandin-mediated renal afferent arteriolar dilation, reducing the pressure gradient that drives glomerular filtration; they also raise the risk of acute kidney injury when combined with renin-angiotensin system inhibitors, particularly in volume-depleted patients.9 Patients with stable coronary artery disease on ACE inhibitors or ARBs should use non-steroidal anti-inflammatory drugs only when necessary and for the shortest possible duration, with regular monitoring of renal function.9
Optimal medical therapy in stable coronary artery disease refers to the combination of maximal antianginal therapy (to control symptoms) with evidence-based cardioprotective background therapy (to reduce major adverse cardiovascular events).1·2 The term is operationally defined by the major randomized trials comparing optimal medical therapy to percutaneous coronary intervention: aspirin plus a second antiplatelet agent (initially); statin at maximally tolerated high-intensity dose; beta-blocker; ACE inhibitor or ARB; and maximally tolerated antianginal therapy (long-acting nitrate, calcium channel blocker, ranolazine as needed).1·2 A patient on aspirin, rosuvastatin 40 mg, bisoprolol 10 mg, ramipril 10 mg, and amlodipine 10 mg represents a reasonably complete optimal medical therapy regimen for stable coronary artery disease. Each element has independent evidence and addresses a distinct pathophysiological component of coronary artery disease progression and event risk.1·2
The COURAGE trial randomized 2,287 patients with stable coronary artery disease and objective evidence of myocardial ischemia to optimal medical therapy alone versus percutaneous coronary intervention plus optimal medical therapy.1 Both groups received aspirin, clopidogrel (for PCI patients for one year), beta-blocker, ACE inhibitor or ARB, long-acting nitrate, and a statin. The primary endpoint was death from any cause or non-fatal myocardial infarction. At a median follow-up of 4.6 years, there was NO significant difference in the primary endpoint between the percutaneous coronary intervention group and the optimal medical therapy group (19.0% versus 18.5%).1 Percutaneous coronary intervention did produce superior symptom relief and greater freedom from angina at one and three years, with the advantage attenuating over time. This trial established that for stable coronary artery disease with objective ischemia, optimal medical therapy is a safe and effective alternative to percutaneous coronary intervention for hard outcomes (death, myocardial infarction), though percutaneous coronary intervention provides better and faster symptom control.1 The implication for prescribers is that every stable angina patient deserves a trial of optimal medical therapy before the decision for revascularization is made, and that quality-of-life improvement from revascularization, though real, must be weighed against the risks of the procedure in each individual patient.1
The ISCHEMIA trial enrolled 5,179 patients with stable coronary artery disease and moderate-to-severe myocardial ischemia on stress testing, randomizing them to a conservative strategy (optimal medical therapy alone, with revascularization reserved for failure) versus an invasive strategy (coronary angiography followed by revascularization if anatomically feasible, plus optimal medical therapy).2 At a median follow-up of 3.2 years, there was NO significant difference in the primary composite endpoint (cardiovascular death, myocardial infarction, resuscitated cardiac arrest, or hospitalization for unstable angina or heart failure).2 The invasive strategy showed an early increase in periprocedural myocardial infarction and a late trend toward reduced spontaneous myocardial infarction; the curves were converging at the time of the trial's completion.2 Among patients with angina at baseline, the invasive strategy produced greater improvement in angina symptoms and quality of life at one year, with the advantage persisting at five years for those with more frequent baseline angina.2 The ISCHEMIA trial confirmed and extended the COURAGE finding: for stable coronary artery disease with even moderate-to-severe ischemia, optimal medical therapy alone is a safe initial strategy for most patients. Referral for revascularization is appropriate when symptoms are unacceptable despite optimal medical therapy, when high-risk anatomy is identified (left main or three-vessel disease with reduced ejection fraction), or when the patient prefers revascularization for quality-of-life reasons after full informed discussion.2
A prescriber managing a patient with newly diagnosed stable coronary artery disease should build the medication regimen in the following sequence, verifying that each layer is addressed before considering the regimen complete.1·2 First, antiplatelet therapy: aspirin 75-100 mg daily; if aspirin is contraindicated, clopidogrel 75 mg daily. Second, statin therapy: high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg); confirm LDL goal achieved at six to twelve weeks and uptitrate if needed; add ezetimibe if high-intensity statin fails to achieve LDL below 70 mg/dL. Third, ACE inhibitor or ARB: initiate in all patients with left ventricular ejection fraction below 40%, hypertension, diabetes, or chronic kidney disease; consider in all others as a Class IIa indication.1·2 Fourth, beta-blocker: first-line antianginal and cardioprotective in post-myocardial infarction; titrate to resting HR 55-60 bpm for antianginal benefit. Fifth, sublingual nitroglycerin: prescribe to all patients with active angina symptoms for acute relief and pre-exertional prophylaxis. Sixth, add antianginal agents for symptom control as needed per the algorithm in ANG-06: long-acting nitrates, calcium channel blockers, ranolazine, ivabradine, with attention to the contraindication and interaction profiles established in the preceding modules. The patient's complete regimen in stable coronary artery disease is therefore a combination of cardioprotective background therapy (aspirin, statin, ACE inhibitor/ARB) plus antianginal symptom therapy (beta-blocker serving both roles, plus add-on agents as needed), with all elements prescribed at evidence-based doses and monitored systematically.1·2
Antiplatelet therapy (aspirin, clopidogrel): no routine laboratory monitoring is required in asymptomatic patients on standard doses; annual review of gastrointestinal bleeding symptoms and assessment of need for proton pump inhibitor co-therapy; assess for signs of occult bleeding (iron deficiency anemia) at each annual review.1·2 Statin therapy: fasting lipid panel and liver function tests at baseline; repeat fasting lipid panel at six to twelve weeks after initiation or dose change to confirm LDL target achievement; routine hepatic enzyme monitoring is no longer recommended in asymptomatic patients (FDA label change 2012); obtain only if symptoms suggestive of hepatotoxicity develop; creatine kinase if myopathy symptoms arise.8 ACE inhibitor or ARB: serum creatinine, blood urea nitrogen, and potassium at one to two weeks after initiation or dose increase; recheck at each titration step; once stable, monitor every three to six months in patients with chronic kidney disease or on concurrent aldosterone antagonist.9 Beta-blocker: resting HR and blood pressure at each visit during titration; ECG if PR interval prolongation or bradycardia reported.2
In stable coronary artery disease, annual medication review should assess whether each agent continues to serve its indication at its current dose, whether dose escalation would be warranted to better achieve targets (LDL, HR, BP), and whether any new drug interactions have been introduced through additions to the regimen.1·2 Particular attention should be given to: statin dose relative to LDL target; undertreatment is common; ACE inhibitor dose; many patients are on subtherapeutic doses that fall short of those used in outcome trials; beta-blocker dose relative to resting HR target; and antiplatelet therapy continuation and any new indication for co-anticoagulation that may alter the antiplatelet strategy. Annual deprescribing review is also appropriate, identifying agents that may no longer be needed (for example, a long-acting nitrate in a patient who has become asymptomatic on optimal medical therapy and where ranolazine or ivabradine can be spaced).1·2
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease (COURAGE). N Engl J Med. 2007;356(15):1503-1516
doi:10.1056/NEJMoa070829Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease (ISCHEMIA). N Engl J Med. 2020;382(15):1395-1407
doi:10.1056/NEJMoa1915922Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477
doi:10.1093/eurheartj/ehz425Patrono C, Morais J, Baigent C, et al. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760-1776
doi:10.1016/j.jacc.2017.08.037Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86
doi:10.1136/bmj.324.7329.71CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339
doi:10.1016/S0140-6736(96)09457-3Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-260
doi:10.1093/eurheartj/ehx419Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350
doi:10.1016/j.jacc.2018.11.003Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (HOPE). N Engl J Med. 2000;342(3):145-153
doi:10.1056/NEJM200001203420301Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (EUROPA). Lancet. 2003;362(9386):782-788
doi:10.1016/S0140-6736(03)14286-9Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22
doi:10.1016/S0140-6736(02)09327-3Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease (PEACE). N Engl J Med. 2004;351(20):2058-2068
doi:10.1056/NEJMoa042739